amy d. rix, interim ceo, founder nosebleed stop the bleed with… nosebleed … inc
TRANSCRIPT
Amy D. Rix, Interim CEO, FounderAmy D. Rix, Interim CEO, Founder
Stop the Bleed with… NONOseseBLEEDBLEED …
Inc.
Problems that can be associated with frequent nosebleeds:
o Embarrassing especially when out in publico Loss of dignityo Loss of clotheso Having to stop what you are doingo Loss of time in a game (sports)
2
Social/Public Issues…Social/Public Issues…
Benefits of NOseBLEED•Is non-invasive to the nose•Does not restrict normal breathing•Stops nosebleeds in ~1-2 minutes•Product is digestible
TechnologyTechnologyTechnology Technology
Solution: Stop the bleed Solution: Stop the bleed with…with…
Technology
Market
• 2003 Study – 440 million total US nosebleeds per yearo Benninger and Marple - medical study (published/peer reviewed)
• 2008 Market Research Study- 700 million recurrent (more than 1 per month)
nosebleeds per yearo Leading online survey company
Sizable NeedSizable Need
Market
• Contract Manufacturing• Joint-venture distributors
―Cardinal Health―McKesson
• Direct sales model―Breathe Right Strips (CNS Inc.)―DURABOND (Closure Medical Corp.)
Partner and Exit OptionsPartner and Exit Options• CPC Licensing/Acquisition Options
―Johnson & Johnson (Closure Medical Corp., DURABOND)―GSK
• Medical Supply Licensing/Acquisition Options ―McKesson―Cardinal Health
Business
Business Model/ExitBusiness Model/Exit
Business
Financials
Financial ReturnFinancial ReturnYear 1 2 3 4 5
($ Millions)
Market Size* $648.0 $673.9 $700.9 $1,403.8 $1,460.0 Market Penetration** 3% 6% 9% 12% 15%
Revenue $19.4 $40.4 $63.1 $168.4 $219.0
Gross Margin $6.6 $13.7 $21.4 $57.3 $74.5 % of Revenue 34% 34% 34% 34% 34%
EBITDA $3.7 $8.8 $14.4 $44.8 $61.3 % of Revenue 18.9% 21.8% 22.8% 26.6% 28.0%
* Total Addressable Market (top 2 market segments yr 1-3, all segments yr 4-5)
** Source 2008 Market Study, Propensity to Buy Results = 18%
Milestones
Seed Round Milestones: • Regulatory opinions -
• Prototypes –
• Material selection –
• Market research –
• Segment strategy -
• FDA approval – Ongoing
• Manufacturing partner(s) – Ongoing
• Sterilization process – Ongoing
~$350K
Series A Milestones:Series A Milestones:
• $100 million revenue$100 million revenue
• Cash flow positiveCash flow positive
• Partner agreement and Partner agreement and exit exit
• IP ContinuationIP Continuation
$2.5 Million$2.5 Million
Value CreationValue Creation
Financials